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Hypertrophic cardiomyopathy (HCM) is an inherited car-
diac muscle disease that affects sarcomeric proteins, result-
ing in severe hypertrophy, myofibrillar disorganization, and
enhanced interstitial fibrosis. The disease is often familial,
with autosomal-dominant transmission. More than 100
different mutations in 10 genes that encode sarcomeric
proteins have been described (1–3). Hypertrophy typically
affects the interventricular septum, but may be concentric or
apically located. The main hemodynamic feature is diastolic
dysfunction with increased filling pressures, delayed relax-
ation, and increased muscle stiffness. Approximately 25% of
all patients have dynamic left ventricular (LV) outflow tract
obstruction with a systolic pressure gradient.
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The great threat of the disease is that affected children
and young adults may die suddenly. However, the incidence
is low: 2% to 3% per year in adults and 4% to 6% in children.
It is the most common cause of sudden death in athletes
and its occurrence is often associated with exercise. Thus,
risk stratification has become a major issue in HCM
(4,5). Approximately 60% to 70% of all patients with
HCM die suddenly. It is generally assumed, although not
established, that sudden death is due to ventricular
arrhythmias (6). The arrhythmic substrate is a combina-
tion of several factors, including hypertrophy, myocardial
fiber disarray, and interstitial fibrosis. Accepted triggers
for ventricular arrhythmias are ischemia, physical exer-
cise, and excessive sympathetic stimulation. The follow-
ing risk factors have been associated with an increased
risk of sudden death.
1. Family history of HCM with sudden cardiac death
2. History of syncopy or presyncopy
3. Massive LV hypertrophy (septal wall thickness 30 mm)
4. Survived sudden cardiac death
5. Nonsustained ventricular tachyarrhythmias (NSVT)
6. Abnormal blood pressure response to exercise
Several other risk factors have been described, but the
severity of the outflow tract obstruction, the degree of
functional limitation, and cardiac symptoms in general did
not correlate with the risk of sudden cardiac death.
In this issue of the Journal, the report by Monserrat et al.
(7), the prognostic importance of repetitive, prolonged, and
symptomatic NSVT has been examined and related to age
and prognosis. A total of 531 patients with HCM were
studied using Holter monitoring (mean 41  11 h). A total
of 104 patients (19.6%) had NSVT, which increased with
age (p  0.008), LV wall thickness (p  0.001), and left
atrial size (p  0.0001). Sixty-eight patients died during
follow-up of 72 months; 32 died suddenly (47%). Mortality
rate was highest in young patients (30 years) with NSVT.
Thus, it was concluded that sudden cardiac death is signif-
icantly increased in young patients with HCM and NSVT.
A relation among frequency, duration, and rate of NSVT
could not be demonstrated.
RECOMMENDATIONS
The implication of the study by Monserrat et al. (7) is that
when NSVTs occur in young patients with HCM, it may
justify implantation of an implantable cardioverter-
defibrillator (ICD) to prevent sudden cardiac death. In
contrast, NSVT in older patients does not justify therapy
when it occurs without other risk factors, such as severe LV
hypertrophy, history of presyncopy or syncopy, or abnormal
blood pressure response to exercise. However, it should be
kept in mind that Holter monitoring identifies only a small
subset of patients at high risk and, therefore, the search for
other risk factors is a must. The current practice for treating
patients with HCM (Fig. 1) should be re-evaluated in the
light that prophylactic implantation of an ICD is always an
option when NSVTs are present.
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Figure 1. Therapeutic strategies in hypertrophic cardiomyopathy (HCM).
ICD  implantable cardioverter-defibrillator; NSVT  nonsustained
ventricular tachyarrhythmias.
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